Global Car-T Therapy Market Size 2024, Forecast To 2033
11 Mar, 2024
The car-t therapy pipeline analysis market size has demonstrated rapid growth, elevating from $2.15 billion in 2023 to $2.55 billion in 2024, showcasing a significant compound annual growth rate (CAGR) of 19.1%. The growth observed in the historic period is linked to increases in healthcare expenditure, a surge in pharmaceutical R&D expenditure, and advancements in drug discovery. Projections for 2028 forecast continued rapid growth, reaching $4.74 billion with a CAGR of 16.7%. The expected growth in the forecast period is attributed to an increase in blood cancer incidence rates, a rise in healthcare expenditure, a strong pipeline of drugs, and an augmented focus on car-t therapy. Major trends in this period encompass investments in R&D to create remodeled car-t therapy, the development of off-the-shelf allogeneic car-t therapy for advanced cancer treatment, the manufacturing of next-generation car-t cells for enhanced treatment of high-grade glioma, investments in AI and machine learning solutions to optimize future car-t therapy, strategic collaborations to boost innovations, and collaboration or acquisition of competitor companies to expand the car-t therapy portfolio.
Global CAR-T Therapy Market Key Driver
The CAR-T therapy market is propelled by the increasing financial support from various organizations dedicated to fostering the development and consumption of CAR-T therapy. Government and non-government entities contribute financial support for research and development activities by companies in the CAR-T therapy market, as well as for patient treatments, particularly for conditions like acute lymphoblastic leukemia (ALL). A notable example is the University of California San Diego School of Medicine, which received a grant of US$4.1 million in December 2021 from the California Institute for Regenerative Medicine (CIRM) governing board to advance novel chimeric antigen receptor (CAR-T) cell therapy. This financial backing from diverse organizations positively influences the growth trajectory of the CAR-T therapy market.
Get A Free Sample Of The Global CAR-T Therapy Market ReportGlobal CAR-T Therapy Market Segments
The car-t therapy pipeline analysis market covered in this report is segmented –
1) By Type: Monotherapy, Combination Therapy
2) By Target Antigen: CD19, CD22, BCMA, Other Target Antigens
3) By Application: Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Other Applications
By Geography:The regions covered in the car-t therapy pipeline analysis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain
North America was the largest region in the CAR-t therapy market in 2023. Western Europe was the second-largest region in the global CAR-T therapy market share. The regions covered in the car-t therapy pipeline analysis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major CAR-T Therapy Industry Players
Gilead Sciences, Novartis AG, Biocon, Gracell Biotechnology Ltd, Aeon Therapeutics, CARsgen Therapeutics, Daiichi Sankyo, Otsuka Pharmaceutical, Ono Pharmaceutical, Japan Tissue Engineering, Nipro Corporation, Takeda Pharmaceutical Company, Astellas Pharma, Innovative Cellular Therapeutics, Cellular Biomedicine Group, PersonGen Biomedicine, Hebei Senlang Biotech, Adaptimmune(UK), Autolus Therapeutics, BioNTech, Cellectis, Celyad, Crescendo Biologics, GammaDelta Therapeutics, Immatics, Biocad, Celgene Corporation, Johnson & Johnson, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Amgen, AstraZeneca, Bayer AG, Merck, Pfizer, Juno Therapeutics, Allogene Therapeutics, Bluebird Bio Amgen, Regen BioPharma, OncoSec Medical Incorporated, Precision BioSciences, Bellicum, Sandoz AG, GlaxoSmithKline plc, Elekta, SudairPharma, Janssen, Aspen, Adcock Ingram
Get The Full Global CAR-T Therapy Market Report
CAR-T Therapy Market Overview
The chimeric antigen receptor -T therapy is a type of immunotherapy in which T-cells are taken from the patient’s blood are modified in a laboratory with the addition of a special protein receptor that grants T-cells the power to recognize as well as kill cancer cells easily, along with infusing the same back into that patient. This special protein receptor, known as the chimeric antigen receptor (CAR), attaches to a specific protein on a patient’s cancer cells. The infused cells multiply and prevail in the patient’s body as living drugs.
CAR-T Therapy Global Market Report 2023 provides data on the global car-t therapy market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The car-t therapy market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.